Baird Reiterates Outperform Rating on Soleno Therapeutics Inc. (SLNO)

Baird analyst Brian Skorney reiterated an Outperform rating and $72.00 price target on Soleno Therapeutics Inc. (NASDAQ: SLNO).

The analyst comments "Positive on regulatory development. This morning, Soleno announced the FDA has decided not to hold an Advisory Committee meeting for DCCR in PWS, and the review remains on track for a decision by the previously stated December 27, 2024 PDUFA. We think this is a positive development, further supporting our confidence in approval as we view the improvements in hyperphagia in the Phase 3 study (ex-Covid) and randomized withdrawal portion as supporting a clear enough efficacy profile for FDA to lean on in its review."

For an analyst ratings summary and ratings history on Soleno Therapeutics Inc. click here. For more ratings news on Soleno Therapeutics Inc. click here.

Shares of Soleno Therapeutics Inc. closed at $47.63 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• Critical One Energy closes second tranche of flow-through placement